LTKfarma pursues development of proprietary TK therapy
Because of lack of sufficient evidence of an imminent marketing of the TK therapy by Molmed, the Court rejected UPMC and LTKfarma’s claims. Nevertheless, considering the claims of UPMC and LTKfarma legitimate in substance, the Court rejected Molmed’s counterclaim for awarding “punitive” damages.
In conclusion, the Italian part of European patent EP 0 564 646 remains in force. UPMC and LTKfarma will pursue their efforts for a proper respect of their rights on proprietary TK therapy.
Most read news
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.